LumiraDx Reports Its COVID-19, Flu A/B Rapid Antigen Test Achieved CE Marking
- Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the simultaneous detection and differentiation of SARS-CoV-2, influenza A, and influenza B viral antigen
- Results in 12
Benzinga Pro’s Top 5 Stocks To Watch For Tuesday, Dec. 7, 2021: INTC, MTOR, ANIX, LMDX, ITI
Today's 5 Stock Ideas:
Intel (INTC) - Shares were up 8% Tuesday morning following late Monday news the company intends to take its driver assistance, autonomous driving solutions unit Mobileye
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
LumiraDx Q3 EPS $0.46 Up From $(0.47) YoY, Sales $109.10M Beat $94.32M Estimate
LumiraDx (NASDAQ:LMDX) reported quarterly earnings of $0.46 per share. This is a 197.87 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $109.10
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
